MA31744B1 - Compositions pharmaceutiques lyophilisees - Google Patents

Compositions pharmaceutiques lyophilisees

Info

Publication number
MA31744B1
MA31744B1 MA32691A MA32691A MA31744B1 MA 31744 B1 MA31744 B1 MA 31744B1 MA 32691 A MA32691 A MA 32691A MA 32691 A MA32691 A MA 32691A MA 31744 B1 MA31744 B1 MA 31744B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
orally
lyophilized pharmaceutical
administered parenterally
buffer
Prior art date
Application number
MA32691A
Other languages
Arabic (ar)
English (en)
Inventor
Thitiwan Buranachokpaisan
Wenlei Jiang
Wei-Qin Tong
Joseph Lawrence Zielinski
Jiahao Zhu
Hans-Peter Zobel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40005335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31744(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31744B1 publication Critical patent/MA31744B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur des compositions pharmaceutiques qui comprennent un composé thérapeutique peu soluble dans l'eau, un solvant aqueux, un chélateur/antioxydant, un tampon ou composant de tampon et un agent diluant. Les compositions pharmaceutiques peuvent être ingérées par voie orale ou administrées par voie parentérale. Les compositions pharmaceutiques peuvent en outre être lyophilisées pour former un agglomérat pharmaceutiquement acceptable, lequel pourra être administré par voie orale, par exemple en tant que forme posologique orale solide ; ou bien reconstitué et administré par voie parentérale, par exemple sous forme de bolus intraveineux ou de perfusion intraveineuse unique, ou par voie orale, par exemple sous forme de solution buvable.
MA32691A 2007-09-20 2010-03-12 Compositions pharmaceutiques lyophilisees MA31744B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97383007P 2007-09-20 2007-09-20
PCT/US2008/076752 WO2009039226A1 (fr) 2007-09-20 2008-09-18 Compositions pharmaceutiques lyophilisées

Publications (1)

Publication Number Publication Date
MA31744B1 true MA31744B1 (fr) 2010-10-01

Family

ID=40005335

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32691A MA31744B1 (fr) 2007-09-20 2010-03-12 Compositions pharmaceutiques lyophilisees

Country Status (20)

Country Link
US (1) US20100331387A1 (fr)
EP (1) EP2205222A1 (fr)
JP (1) JP2010540445A (fr)
KR (1) KR20100059887A (fr)
CN (1) CN101801345A (fr)
AR (1) AR068822A1 (fr)
AU (1) AU2008302273A1 (fr)
BR (1) BRPI0817118A2 (fr)
CA (1) CA2696914A1 (fr)
CL (1) CL2008002786A1 (fr)
CO (1) CO6270207A2 (fr)
EC (1) ECSP10010039A (fr)
GT (1) GT201000062A (fr)
MA (1) MA31744B1 (fr)
MX (1) MX2010002970A (fr)
PE (1) PE20090706A1 (fr)
RU (1) RU2010115262A (fr)
TN (1) TN2010000097A1 (fr)
TW (1) TW200930416A (fr)
WO (1) WO2009039226A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2743740T3 (es) * 2016-03-31 2020-02-20 Midatech Ltd Aducto de ciclodextrina-panobinostat

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
ES2297490T3 (es) * 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
US20060270730A1 (en) * 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
US20060128660A1 (en) * 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
WO2006094068A2 (fr) * 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Inhibiteurs d’hdac favorisant l’expression des brm et diagnostics associes aux brm
BRPI0806341A2 (pt) * 2007-01-10 2011-09-06 Novartis Ag formulações de inibidores de desacetilase
BRPI0807812A2 (pt) * 2007-02-15 2020-06-23 Novartis Ag Combinações de lbh589 com outros agentes terapêuticos para tratar câncer

Also Published As

Publication number Publication date
CN101801345A (zh) 2010-08-11
TW200930416A (en) 2009-07-16
AR068822A1 (es) 2009-12-09
JP2010540445A (ja) 2010-12-24
GT201000062A (es) 2012-03-30
KR20100059887A (ko) 2010-06-04
MX2010002970A (es) 2010-04-01
CA2696914A1 (fr) 2009-03-26
AU2008302273A1 (en) 2009-03-26
RU2010115262A (ru) 2011-10-27
US20100331387A1 (en) 2010-12-30
WO2009039226A1 (fr) 2009-03-26
EP2205222A1 (fr) 2010-07-14
BRPI0817118A2 (pt) 2019-09-24
ECSP10010039A (es) 2010-04-30
CL2008002786A1 (es) 2009-05-15
TN2010000097A1 (en) 2011-09-26
CO6270207A2 (es) 2011-04-20
PE20090706A1 (es) 2009-07-15

Similar Documents

Publication Publication Date Title
JP6777366B2 (ja) スルホラファンとシリマリン及び／又はシリビニンを含有してなるオオアザミ抽出物または粉末を含む組成物
MA27710A1 (fr) Formulations pharmaceutiques liquides de palonosetrone
MA38576A1 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA29681B1 (fr) Formes galeniques du risedronate
MA32027B1 (fr) Preparation de capsules
MA31663B1 (fr) Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe
WO2005065646A3 (fr) Compositions medicamenteuses et formes pharmaceutiques
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
WO2006108405A3 (fr) Conjugues de nanoparticules et d'agents actifs
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
RS114004A (en) Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
WO2007002181A3 (fr) Derives tetrahydrocarbazole convenant comme modulateurs du recepteur d'angrogene
MA34296B1 (fr) Composition retard injectable antipsychotique
MA33553B1 (fr) Procede pour traiter un patient a risque de developper un ulcere associe aux ains
MA34553B1 (fr) Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
NO20076595L (no) Behandling av leversykdommer hvor jern spiller en rolle i patogenesen
MA32275B1 (fr) Preparations orales et injectables de composes de tetracycline
HK1119596A1 (en) Use of yrazolopyrimidinone derivative in the preparation of agent for the prevention and treatment of liver diseases
CO2021005221A2 (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
WO2008008882A3 (fr) Modulateur du récepteur des glucocorticoïdes et procédés d'utilisation
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
MA29333B1 (fr) Preparations pharmaceutiques d'aerosol pour aerosols-doseurs pressurises contenant un agent sequestrant
MA31744B1 (fr) Compositions pharmaceutiques lyophilisees
MXPA06007510A (es) Composiciones de farmaco y formas de dosis novedosas de topiramato.